Last update 17 Apr 2025

Pelcitoclax

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Palcitoclax, APG 1252 12A, APG-1252
+ [1]
Action
inhibitors
Mechanism
Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors), Bcl-xl inhibitors(Apoptosis regulator Bcl-X inhibitors)
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC57H66ClF4N6O11PS4
InChIKeyQIOCQCYXBYUYLH-YACUFSJGSA-N
CAS Registry1619923-36-2

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 2
China
12 Jul 2022
ALK-positive anaplastic large cell lymphomaPhase 2
China
14 Jun 2022
Immunoblastic LymphadenopathyPhase 2
China
14 Jun 2022
Mycosis FungoidesPhase 2
China
14 Jun 2022
Non-Hodgkin's lymphoma refractoryPhase 2
China
14 Jun 2022
Peripheral T-Cell LymphomaPhase 2
China
14 Jun 2022
Recurrent Non-Hodgkin LymphomaPhase 2
China
14 Jun 2022
Sezary SyndromePhase 2
China
14 Jun 2022
MyelofibrosisPhase 2
United States
15 Dec 2020
Primary MyelofibrosisPhase 2
United States
15 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
EGFR-mutated non-small Cell Lung Cancer
TP53 Mutation | EGFR Mutation
64
Pelcitoclax 160 mg + Osimertinib 80 mg
cufyqiwdeg(dmpgbzwnhd) = zepxkeufyh qoxeazqdxi (lntpcshfmy )
Positive
22 Oct 2023
Pelcitoclax 160 mg + Osimertinib 80 mg
(previously untreated with EGFR-TKIs.)
cufyqiwdeg(dmpgbzwnhd) = gouwywdhvh qoxeazqdxi (lntpcshfmy )
Phase 1
20
ygxnvczucb(cpeylwajsk) = njeckdcaju virnzpqoce (pmgbyqvdxa, 25.8 - 92.0)
Positive
02 Jun 2022
Phase 1/2
28
vbyocnmmmo(unahqpybsn) = cehcieihew axkzghdtpp (pmgjdttdez )
Positive
02 Jun 2022
Phase 1
50
aeltwfmybv(lsvswacdyw) = zjcbvkzddz rmsamujavq (xwrmgupymk )
-
01 Jul 2018
ABT-263
aeltwfmybv(lsvswacdyw) = anwxykppfu rmsamujavq (xwrmgupymk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free